Christian Weigel, MD
Internal Medicine · Morehead, KYNPI 1083677421
Payments from drug & device makers
Across 553 payments — averaging $14.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$892
- Lilly USA, LLC$850
- AbbVie$799
- Astellas Pharma US Inc$619
- Pfizer$563
- plus $3K from 31 others
What the payments were for
- Food & beverage$8,02398%
- Education$1422%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 101 | $1,180 |
| AstraZeneca | 40 | $892 |
| Lilly USA, LLC | 69 | $850 |
| AbbVie(2 entities) | 54 | $799 |
| Astellas Pharma US Inc | 31 | $619 |
| Pfizer | 41 | $563 |
| Boehringer Ingelheim | 40 | $512 |
| GSK | 27 | $473 |
| Novartis | 26 | $373 |
| Mylan Specialty L.p. | 13 | $217 |
| Bayer | 11 | $165 |
| Sumitomo Pharma America, Inc. | 8 | $145 |
| Merck | 15 | $134 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $130 |
| Esperion Therapeutics, Inc. | 7 | $126 |
| Amgen | 6 | $116 |
| Sanofi-aventis U.S. LLC | 7 | $93 |
| Abbott | 5 | $82 |
| Otsuka America Pharmaceutical, Inc. | 4 | $76 |
| Radius Health, Inc. | 5 | $72 |
| Lundbeck LLC | 4 | $64 |
| Amarin Pharma, Inc. | 4 | $62 |
| Vanda Pharmaceuticals Inc. | 2 | $52 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $51 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Biohaven Pharmaceuticals, Inc. | 2 | $35 |
| Sunovion Pharmaceuticals Inc. | 4 | $33 |
| Xeris Pharmaceuticals, Inc. | 2 | $32 |
| Johnson & Johnson | 2 | $29 |
| Antares Pharma, Inc. | 1 | $28 |
| Exact Sciences | 2 | $27 |
| Phadia US Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Alkermes, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,166 in reported general payments places this provider in the 90th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 278 | $180,828 |
| JardianceEmpagliflozin | 104 | $97,448 |
| OzempicSemaglutide | 80 | $87,224 |
| FarxigaDapagliflozin Propanediol | 98 | $70,513 |
| EntrestoSacubitril/Valsartan | 89 | $66,573 |
| XareltoRivaroxaban | 148 | $65,099 |
| LinzessLinaclotide | 65 | $47,897 |
| MyrbetriqMirabegron | 65 | $34,135 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $28,893 |
| TrulicityDulaglutide | 19 | $28,146 |
| RybelsusSemaglutide | 26 | $22,228 |
| NuedextaDextromethorphan Hbr/Quinidine | 34 | $20,140 |
| MounjaroTirzepatide | 20 | $19,955 |
| ProcritEpoetin Alfa | 23 | $12,616 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 56 | $12,336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $563 | $180,828278 claims |
| Novo NordiskOzempic, Rybelsus | $1,180 | $109,452106 claims |
| Boehringer IngelheimJardiance | $512 | $97,448104 claims |
| Johnson & JohnsonXarelto, Procrit | $29 | $77,715171 claims |
| AstraZenecaFarxiga | $892 | $70,51398 claims |
| NovartisEntresto | $373 | $66,57389 claims |
| AbbVieLinzess, Synthroid | $799 | $51,464114 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $850 | $48,10039 claims |
| Astellas Pharma US IncMyrbetriq | $619 | $34,13565 claims |
| GSKTrelegy Ellipta | $473 | $28,89341 claims |
| MerckJanuvia | $134 | $10,96912 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $12 | $9,56239 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Morehead
- Mark AdamsLondon$15.4M
- Matthew WenkerErlanger$12.8M
- Jason ChesneyLouisville$6.3M
- Neil FarrisLexington$3M
- David JohnsonOwensboro$787K
- Hollis ClarkMurray$780K
- Fares KhaterWhitesburg$412K
- Christopher PhillipsPaducah$315K
- Cynthia Bowman-StroudPaducah$234K
- Bernard BuchananOwensboro$224K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.